Institutional members access full text with Ovid®

Share this article on:

Use of Ceftaroline in the Management of Vertebral Osteomyelitis: Case Report

Zainah, Hadeel MD; Hammoud, Marwa MD; Vazquez, Jose A. MD

Infectious Diseases in Clinical Practice: July 2013 - Volume 21 - Issue 4 - p 269–271
doi: 10.1097/IPC.0b013e318276959f
Case Reports

Ceftaroline is a novel broad-spectrum cephalosporin that has activity against gram-negative and gram-positive bacteria including methicillin-resistant Staphylococcus aureus. It was approved by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in October 2010. We report 2 cases of S aureus vertebral osteomyelitis treated effectively with ceftaroline.

From the Division of Infectious Disease, Henry Ford Hospital, Detroit, MI.

Correspondence to: Hadeel Zainah, MD, Henry Ford Hospital, 2799 W Grand Blvd, CFP 304, Detroit, MI, 48202. E-mail:

Disclosure: Hadeel Zainah and Marwa Hammoud have no funding or conflicts of interest to disclose. Jose A. Vazquez is in the speakers’ bureaus of Pfizer, Astellas, Merck, and Forest.

Hammoud and Zainah contributed equally to the manuscript.

© 2013 by Lippincott Williams & Wilkins.